Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Which Store is Your Decision ? - 2A Manual for Well known Western television Series
- 3Hamas Navy head, engineer of Khan Yunis tunnel network killed in Gaza, IDF confirms
- 4Bring tissues and skip the mascara: The movie that's making theater-goers sob uncontrollaby
- 5Excelling at Discussion: Genuine Examples of overcoming adversity
- This Flashy Old-School Design Trend From Italy Still Has A Place In Modern Kitchens
- Mississippi Insight for Jan. 11, 2026
- A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
- Wegmans recalls mixed nuts over salmonella contamination fears
- Commonsense Ways to work on Your Funds with a Restricted Pay
- 7 Espresso Machines for Home Baristas
- All the ways Marjorie Taylor Greene has shifted her approach lately — and why Trump is 'surprised at her'
- Elanco's drug gets emergency nod to treat deadly flesh-eating parasite in cats
- Do-It-Yourself Home Style on a Careful spending plan: Imaginative Thoughts and Tasks
